$uniQure NV (QURE.US)$uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy 4 MINUTES AGO, 7:05 AM EST VIA GLOBENEWSWIRE
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more